{"product_id":"the-future-of-liver-medicine-embracing-change-in-hepatology","title":"The Future of Liver Medicine: Embracing Change in Hepatology","description":"\u003cp\u003eIn this forward-looking review, two liver specialists from the Icahn School of Medicine at Mount Sinai examine how five major scientific and societal shifts will transform the field of hepatology (the study and treatment of liver disease) over the next 35 years. Drawing on dramatic advances from the past three decades, the authors predict that precision medicine, stem cell therapies, nanotechnology, health care reorganization, and mobile health technology will reshape the way liver disease is prevented, diagnosed, and treated. The review also highlights the rising threat of nonalcoholic steatohepatitis (NASH) and calls on future hepatologists to embrace change as an essential mark of wisdom in their field.\u003c\/p\u003e\n\n\u003ch1\u003eThe Future of Liver Medicine: Embracing Change in Hepatology\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#introduction\"\u003eBackground: Why This Review Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#five-shifts\"\u003eFive Major Forces Transforming Liver Care\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#precision-medicine\"\u003ePrecision Medicine: Your Genes, Your Treatment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#stem-cells\"\u003eStem Cells and Tissue Repair: Regenerating the Liver\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#nanotechnology\"\u003eNanotechnology and Imaging: Seeing and Healing Better\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#cost-containment\"\u003eCost Containment and New Models of Care\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#patient-empowerment\"\u003ePatient Empowerment: The Rise of Mobile Health\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#changing-disease\"\u003eThe Changing Landscape of Liver Disease\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#nash\"\u003eNASH: The Emerging Epidemic\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#workforce\"\u003eThe Future Liver Specialist\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of This Review\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients Today\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePrecision medicine uses genetic information, such as the IL-28 gene polymorphism, to tailor hepatitis C treatment and guide liver cancer therapy.\u003c\/li\u003e\n\u003cli\u003eStem cell biology and cellular plasticity may enable cell-based therapies that accelerate liver tissue repair, potentially helping patients with cirrhosis.\u003c\/li\u003e\n\u003cli\u003eNanotechnology is yielding noninvasive diagnostics, precision drug delivery, and scaffolds for liver tissue support and repair.\u003c\/li\u003e\n\u003cli\u003eNonalcoholic steatohepatitis (NASH) is an emerging epidemic, with greater genetic risk in South and East Asians and Hispanics.\u003c\/li\u003e\n\u003cli\u003eMobile health technologies empower patients by relaying medical information directly to them and enabling constant monitoring of health metrics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"introduction\"\u003eBackground: Why This Review Matters\u003c\/h2\u003e\n\u003cp\u003eHepatology — the branch of medicine focused on the liver, gallbladder, and bile ducts — has experienced nothing short of astonishing progress over the past 35 years. According to Dr. Scott L. Friedman and Yael L. Friedman, the authors of this review, the pace of change is only going to accelerate. Looking ahead, they suggest that the next 35 years will bring advances so profound that the field \"may be unrecognizable by today's standards.\"\u003c\/p\u003e\n\u003cp\u003eThere's a tendency in science to underestimate how much things will change over a decade or more. The authors quote American astronaut Neil Armstrong, who famously observed: \"Science has not yet mastered prophecy. We predict too much for the next year and far too little for the next 10.\"\u003c\/p\u003e\n\u003cp\u003eFor patients, this means the way liver disease is managed today — the tests you receive, the medications you take, and even the doctors you see — will likely look very different in the years to come. The good news is that these changes are designed to make care more personalized, more effective, and more prevention-focused.\u003c\/p\u003e\n\n\u003ch2 id=\"five-shifts\"\u003eFive Major Forces Transforming Liver Care\u003c\/h2\u003e\n\u003cp\u003eThe authors identify five paradigm shifts — fundamental changes in how medicine is understood and practiced — that are already transforming the field of hepatology. These shifts span everything from the tiniest building blocks of the body (cells and genes) to the largest (society and health care systems).\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe genomic and epigenomic revolution:\u003c\/strong\u003e Advances in genetics that make personalized \"precision medicine\" possible.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStem cell biology and cellular plasticity:\u003c\/strong\u003e The ability to reprogram adult cells, accelerate tissue repair, and design cell-based therapies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNanotechnology and imaging:\u003c\/strong\u003e New noninvasive diagnostic tools, cellular delivery systems, and scaffolds for tissue support and repair.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCost containment:\u003c\/strong\u003e Rising pressure to prevent disease and reorganize health care delivery systems.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePatient empowerment:\u003c\/strong\u003e Mobile technologies that relay medical information directly to patients and increase their engagement in decision-making.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eEach of these shifts affects how liver diseases like hepatitis B (HBV), hepatitis C (HCV), cirrhosis, and liver cancer will be managed in the future.\u003c\/p\u003e\n\n\u003ch2 id=\"precision-medicine\"\u003ePrecision Medicine: Your Genes, Your Treatment\u003c\/h2\u003e\n\u003cp\u003eThe first and perhaps most significant shift is the genomic and epigenomic revolution. This has given rise to the concept of \"precision medicine\" — the idea that treatments can be tailored to an individual's genetic makeup. In fact, President Obama identified precision medicine as a high priority for funding by the U.S. National Institutes of Health (NIH), according to the review.\u003c\/p\u003e\n\u003cp\u003eScientists are now able to classify diseases in entirely new ways, using genetic and epigenetic information. Epigenetic changes are modifications that affect how genes behave without changing the underlying DNA sequence. These changes can be influenced by the environment, the microbiome (the community of bacteria living in and on your body), social interactions, and even parental behaviors.\u003c\/p\u003e\n\u003cp\u003eWhat does this mean for you as a patient? Imagine a doctor being able to look at your genetic profile and know in advance whether a medication will work for you — or cause harmful side effects. That's the promise of precision medicine.\u003c\/p\u003e\n\u003cp\u003eThe review gives a concrete example: the discovery of a polymorphism (a naturally occurring variation) in the \u003cem\u003eIL-28\u003c\/em\u003e gene that affects how well patients with hepatitis C respond to treatment with alpha interferon. Although this specific finding would have had a far greater impact a decade earlier, it illustrates exactly how genetics can guide treatment decisions.\u003c\/p\u003e\n\u003cp\u003eThis reliance on genomics will also extend to the management of primary liver cancer, including both intrahepatic cholangiocarcinoma (a cancer of the bile ducts within the liver) and hepatocellular carcinoma (the most common type of liver cancer). Because these tumors are highly heterogeneous — meaning cancer cells within the same tumor can be genetically different from one another — personalized therapy is absolutely essential.\u003c\/p\u003e\n\n\u003ch2 id=\"stem-cells\"\u003eStem Cells and Tissue Repair: Regenerating the Liver\u003c\/h2\u003e\n\u003cp\u003eThe second major shift involves advances in stem cell biology and cellular plasticity. Cellular plasticity refers to the ability of cells to change their identity — for example, an adult cell being \"reprogrammed\" to become a different type of cell that could help repair damaged tissue.\u003c\/p\u003e\n\u003cp\u003eThese advances open the door to exciting possibilities for liver disease. In the future, doctors may be able to use cell-based therapies to accelerate tissue repair, helping the liver regenerate after injury. This could be particularly important for patients with cirrhosis, a condition in which the liver becomes scarred and loses its ability to function.\u003c\/p\u003e\n\n\u003ch2 id=\"nanotechnology\"\u003eNanotechnology and Imaging: Seeing and Healing Better\u003c\/h2\u003e\n\u003cp\u003eThe third shift comes from noteworthy developments in nanotechnology and imaging. Nanotechnology involves engineering materials at an almost unimaginably small scale — a nanometer is one-billionth of a meter.\u003c\/p\u003e\n\u003cp\u003eThese innovations are yielding new tools that benefit patients in several ways:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNoninvasive diagnostics:\u003c\/strong\u003e Tests that can detect liver disease without needles or surgical procedures.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCellular delivery systems:\u003c\/strong\u003e Tiny particles that can deliver medications precisely to where they're needed in the body.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScaffolds for tissue support and repair:\u003c\/strong\u003e Structures that help damaged liver tissue rebuild itself.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor patients, this could mean earlier detection of liver problems, fewer invasive procedures, and more effective treatments with fewer side effects.\u003c\/p\u003e\n\n\u003ch2 id=\"cost-containment\"\u003eCost Containment and New Models of Care\u003c\/h2\u003e\n\u003cp\u003eThe fourth shift is the rising pressure to contain health care costs. This is being driven by a focus on preventing disease in the first place, rather than just treating it once it develops.\u003c\/p\u003e\n\u003cp\u003eIn the United States, this shift is reflected in the movement toward Accountable Care Organizations (ACOs) — networks of doctors and hospitals that work together to coordinate care, with the goal of improving quality while reducing costs. The authors note that these organizations intend to integrate care and enhance health care delivery through population management (managing the health of entire groups of people rather than just individual patients).\u003c\/p\u003e\n\u003cp\u003eThis could actually increase patient access to liver specialists. If population management helps patients see a hepatologist earlier in the course of their disease, specialists can focus more on screening, health care maintenance, and disease prevention — rather than spending all their time managing advanced illness.\u003c\/p\u003e\n\n\u003ch2 id=\"patient-empowerment\"\u003ePatient Empowerment: The Rise of Mobile Health\u003c\/h2\u003e\n\u003cp\u003eThe fifth and final shift is patient empowerment through mobile technology. Smartphones and other mobile devices are dramatically affecting medical care across many specialties, including gastroenterology and hepatology.\u003c\/p\u003e\n\u003cp\u003ePatients now have access to apps and devices that can:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eRelay medical information directly to them\u003c\/li\u003e\n  \u003cli\u003eHelp them monitor their own health metrics\u003c\/li\u003e\n  \u003cli\u003eProvide instant information about their condition\u003c\/li\u003e\n  \u003cli\u003eEnable constant monitoring of important health indicators\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis technology makes patients more active participants in their own care. Instead of being passive recipients of medical advice, patients can track their progress, understand their disease better, and take part in shared decision-making with their doctors.\u003c\/p\u003e\n\n\u003ch2 id=\"changing-disease\"\u003eThe Changing Landscape of Liver Disease\u003c\/h2\u003e\n\u003cp\u003eWith the emergence of highly effective oral (taken by mouth) therapies that can cure hepatitis C, and medications that can suppress hepatitis B, the mix of conditions that liver specialists treat is changing. The review authors also anticipate future curative therapies for hepatitis B.\u003c\/p\u003e\n\u003cp\u003eAs these infectious diseases become more manageable, other liver diseases will make up a growing share of a hepatologist's practice. Two conditions in particular stand out:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAlcoholic liver disease:\u003c\/strong\u003e The authors describe this as \"a terribly neglected public health threat.\" Despite years of effort, the medical community has been unable to curtail high-risk drinking or prevent severe liver injury in people who drink to excess. No imminent improvements are expected.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNonalcoholic steatohepatitis (NASH):\u003c\/strong\u003e A severe form of fatty liver disease not caused by alcohol, NASH is rapidly becoming the dominant concern in liver clinics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"nash\"\u003eNASH: The Emerging Epidemic\u003c\/h2\u003e\n\u003cp\u003eNonalcoholic steatohepatitis, or NASH, is likely to eclipse all other illnesses managed by liver specialists in the near future. The driving force behind this trend is the astonishing rise in obesity worldwide — a problem so severe that, as the authors note, obesity now affects more individuals worldwide than malnutrition.\u003c\/p\u003e\n\u003cp\u003eSome populations are at particularly high risk. The review highlights that NASH poses a special threat among:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSouth and East Asians\u003c\/li\u003e\n  \u003cli\u003eHispanics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese groups appear to have a greater genetic risk of developing the disease, and they may develop NASH at lower body mass indexes (BMIs) than individuals of European descent. This is an important reminder that liver disease risk is not the same for everyone — genetic background and ethnicity play a significant role.\u003c\/p\u003e\n\n\u003ch2 id=\"workforce\"\u003eThe Future Liver Specialist\u003c\/h2\u003e\n\u003cp\u003eThe liver specialist of the future will need a very different set of skills than the hepatologist of today. Because hepatology is a \"highly cognitive\" discipline — meaning it relies heavily on thinking, analysis, and clinical judgment rather than surgical procedures — practitioners will need to become skilled in applying big data solutions to prevent, diagnose, and treat disease.\u003c\/p\u003e\n\u003cp\u003eFor \u003cstrong\u003epediatric hepatologists\u003c\/strong\u003e (specialists who treat children with liver disease), the future will involve interpreting whole genome sequences of parents and fetuses. They will also need to understand how maternal exposures during pregnancy affect epigenetic regulation, and how these changes influence the risk of liver disease in newborns. This information will be essential for assessing neonatal liver disease risk and managing these disorders.\u003c\/p\u003e\n\u003cp\u003eFor \u003cstrong\u003eadult hepatologists\u003c\/strong\u003e, customizing therapies will require the application of pharmacogenomic data (information about how genes affect a person's response to drugs) to optimize the choice and dosing of medications. The IL-28 gene polymorphism story in hepatitis C is just one example of how genetics can guide treatment.\u003c\/p\u003e\n\u003cp\u003eThe reliance on genomics will extend to managing primary liver cancer, where the heterogeneity (genetic diversity) of tumors makes personalized therapy essential. The authors suggest that as newer targeted approaches for cancer continue to evolve, hepatologists should remain comfortable administering these treatments, alongside oncologists. Their rationale? The side effect profiles of these newer targeted therapies are likely to be no worse than those of the interferon-based therapies for hepatitis C, which hepatologists already manage routinely.\u003c\/p\u003e\n\u003cp\u003eBy the year 2050, the provider will need to integrate \"the principles of thoughtful, humane clinical care with an increasingly sophisticated number of datasets\" when advising patients and making sound clinical decisions. In other words, the best liver doctor of the future will be both a compassionate caregiver and a data-savvy analyst.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eThese changes carry significant implications for anyone living with — or at risk for — liver disease:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore personalized treatment:\u003c\/strong\u003e Genetic testing will help doctors choose the right medication and the right dose for each individual patient.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBetter prevention:\u003c\/strong\u003e With advances in understanding genetic risk, doctors may be able to identify who is at risk for liver disease long before symptoms appear.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEarlier access to specialists:\u003c\/strong\u003e Reorganized health care delivery could get patients to liver specialists sooner in the course of their disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMore patient involvement:\u003c\/strong\u003e Mobile health technologies will give patients more information and more control over their care.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eA growing focus on NASH:\u003c\/strong\u003e As hepatitis C becomes curable and hepatitis B becomes more controllable, NASH and alcoholic liver disease will increasingly capture the attention of the medical community — which could lead to better treatments and prevention strategies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe authors also stress that these efforts must extend to the developing world, where both infectious liver diseases and NASH are expected to persist. Liver care in the future will need to be a global effort, not just a concern for wealthy nations.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of This Review\u003c\/h2\u003e\n\u003cp\u003eIt's important to understand what this article is — and isn't. This is a \u003cem\u003ereview article\u003c\/em\u003e, not a clinical study. It presents the authors' expert opinions and projections based on their knowledge of the field, rather than experimental data from a specific research study.\u003c\/p\u003e\n\u003cp\u003eAs the Neil Armstrong quote at the beginning of the article reminds us, predictions about the future are inherently uncertain. The authors themselves acknowledge that \"the future of hepatology will include vistas that we cannot yet fully envision.\" Some advances they anticipate may arrive later than expected, while other breakthroughs they never predicted may change the field entirely.\u003c\/p\u003e\n\u003cp\u003eAdditionally, the review is written from the perspective of American medicine, and some of the specific structural changes mentioned (like Accountable Care Organizations) are specific to the U.S. health care system. Patients in other countries may experience these changes differently.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients Today\u003c\/h2\u003e\n\u003cp\u003eWhile the future holds great promise, there are steps patients can take \u003cem\u003eright now\u003c\/em\u003e to protect their liver health:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your risk:\u003c\/strong\u003e If you are of South Asian, East Asian, or Hispanic descent, talk to your doctor about your risk for NASH, even at lower body weights.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMaintain a healthy weight:\u003c\/strong\u003e Given the close link between obesity and NASH, weight management remains one of the most powerful tools for preventing liver disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimit alcohol consumption:\u003c\/strong\u003e Alcoholic liver disease remains a major public health threat, and the best protection is moderation or abstinence.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGet tested for hepatitis B and C:\u003c\/strong\u003e With highly effective oral treatments now available for hepatitis C, early detection can lead to a cure. Hepatitis B can be suppressed with medication.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about genetic testing:\u003c\/strong\u003e As precision medicine becomes more widely available, ask your doctor whether genetic or pharmacogenomic testing could help guide your treatment decisions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUse technology to your advantage:\u003c\/strong\u003e Consider mobile health apps that can help you track your health metrics and stay engaged in your care.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay informed:\u003c\/strong\u003e The field of liver disease is changing rapidly. Keep an open dialogue with your health care provider about new diagnostic and treatment options that may be relevant to your condition.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThe authors conclude with a hopeful message: \"Though the future of hepatology will include vistas that we cannot yet fully envision, embracing these changes will be a mark of our wisdom.\" For patients, embracing change means staying informed, staying engaged, and working with your health care team to take advantage of the remarkable advances on the horizon.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eI am of South Asian or Hispanic descent. Should I worry about NASH even if my weight is normal?\u003c\/h3\u003e\n\u003cp\u003eThe review says South and East Asians and Hispanics appear to have a greater genetic risk for NASH, and they may develop it at lower body mass indexes than people of European descent. If you belong to these groups, talk to your doctor about your risk even if your weight is not high. Weight management remains a key preventive step.\u003c\/p\u003e\n\u003ch3\u003eWhat is precision medicine for liver disease?\u003c\/h3\u003e\n\u003cp\u003ePrecision medicine means treatments are tailored to your genetic makeup. For example, a variation in the IL-28 gene affects how well patients with hepatitis C respond to alpha interferon. Genetic testing may help doctors choose the right medication and dose for you, and it is also expected to guide liver cancer therapy.\u003c\/p\u003e\n\u003ch3\u003eHow will nanotechnology improve liver diagnosis and treatment?\u003c\/h3\u003e\n\u003cp\u003eNanotechnology is yielding noninvasive diagnostic tests that can detect liver disease without needles, tiny particles that deliver medications precisely where needed, and scaffolds that help damaged liver tissue rebuild. For patients, this could mean earlier detection, fewer invasive procedures, and more effective treatment with fewer side effects.\u003c\/p\u003e\n\u003ch3\u003eHow can mobile health technology help me manage liver disease?\u003c\/h3\u003e\n\u003cp\u003eMobile health technology gives patients direct access to medical information, helps monitor personal health metrics, and enables constant monitoring of important indicators. This makes you a more active participant in your care and supports shared decision-making with your doctor. Apps and devices are already affecting gastroenterology and hepatology.\u003c\/p\u003e\n\u003ch3\u003eWhat will the future liver specialist do differently?\u003c\/h3\u003e\n\u003cp\u003eFuture liver specialists will combine humane clinical care with large datasets. Pediatric specialists may interpret whole genome sequences of parents and fetuses; adult specialists will use pharmacogenomic data to customize medication choice and dose. They may also manage targeted cancer therapies alongside oncologists, using principles of thoughtful, data-informed care.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion for NASH or fatty liver disease if I am of South Asian or Hispanic descent?\u003c\/h3\u003e\n\u003cp\u003eYes, a second opinion can be valuable, especially if you are of South Asian, East Asian, or Hispanic descent, as these groups have a greater genetic risk for NASH and may develop it at lower body weights. A specialist can review your diagnosis, confirm whether you have NASH, and discuss personalized prevention and treatment strategies. Since NASH is an emerging epidemic and management is evolving, an independent expert review can help ensure you receive the most current care. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e The Future of Hepatology: Embrace Change\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47459114975388,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com.br\/products\/the-future-of-liver-medicine-embracing-change-in-hepatology","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}